(ta-floo-prost) ,


(trade name)


Therapeutic: ocular hypotensive agent
Pharmacologic: prostaglandins
Pregnancy Category: C


Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.


Acts as a prostaglandin analogues that decreases intraocular pressure by ↑ uveoscleral outflow.

Therapeutic effects

↓ intraocular pressure.


Absorption: Absorbed through cornea and is converted to the active metabolite tafluprost acid.
Distribution: Unknown.
Metabolism and Excretion: Further metabolized and eliminated.
Half-life: Unknown.

Time/action profile (↓ in intraocular pressure)

Ophthwithin 2–4 hr12 hr24 hr


Contraindicated in: Pediatric: Avoid use in children due to unknown safety of chronic ↑ pigmentation.
Use Cautiously in: Aphakia, pseudoaphakia with a torn posterior lens capsule; Known risk factors for macular edema; Obstetric: Women with child-bearing potential should practice adequate contraception; Lactation: Use cautiously in nursing women.

Adverse Reactions/Side Effects

Ear, Eye, Nose, Throat

  • conjunctival hyperemia (most frequent)
  • blurred vision
  • cataract
  • permanent iris pigmentation
  • eyelid pigmentation
  • lash pigmentation/increased thickness/↑ number
  • macular edema
  • ocular stinging/irritation


Drug-Drug interaction

Note noted.


Ophthalmic (Adults) One drop once daily (into conjunctival sac) in the evening into affected eye(s).


Ophthalmic solution : 0.0015% in 0.3 mL single-use containers

Nursing implications

Nursing assessment

  • Measure intraocular pressure periodically during therapy.

Potential Nursing Diagnoses

Readiness for enhanced knowledge, related to medication regimen (Patient/Family Teaching)


  • Ophthalmic: Wash hands prior to instillation. Pull lower lid downward and look up. Instill 1 drop in conjunctival sac each evening. Each unit is for one-time use; discard after using. Store unopened foil pouches in refrigerator. Do not open pouch until ready to use.
    • If used with other ophthalmic medications, administer at least 5 min apart.

Patient/Family Teaching

  • Instruct patient to use drops as directed. Do not use more than 1 drop daily; may increase intraocular pressure. Do not use for a condition for which it was not prescribed. Do not share with others, even if they have the same symptoms; may cause harm.
  • Advise patient to read the Patient Information Leaflet prior to initiating therapy and with each Rx refill in case of changes.
  • Inform patient of potential side effects including brownish color of the iris; may be permanent. Also, darkening of the eyelid, increasing length, thickness, color, or number of eyelashes, and hair growth on eyelids; usually reversible.
  • Advise patient to notify health care professional if eye injury, eye infection, sudden loss of vision, eye surgery, swelling and redness around eye, or problems with eyelids occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient use adequate contraception during therapy and to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

Evaluation/Desired Outcomes

  • Reduction of intraocular pressure.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Healthcare company Meiji Seika Pharma Co Ltd revealed on Tuesday the availability of DIQUAS ophthalmic solution 3% (Diquafosol Sodium) and TAFLOTAN ophthalmic solution 0.0015% (Tafluprost) in Indonesia.
Januleviciene et al found significant improvements in corneal staining, TBUT, subjective comfort and tear osmolarity when patients were changed from BAK-preserved latanoprost to preservative-free tafluprost. (22) In just 12 weeks, tear osmolarity had significantly reduced from an average of 315.7[+ or -]15.1mOsm/L to 302.0[+ or -]9.9mOsm/L.
The currently prescribed PGAs in our region are bimatoprost 0.01% (with BAK 0.02%), latanoprost 0.005% (with BAK 0.02%), travoprost 0.004% (with 0.001% polyquad), and tafluprost 0.0015% (preservative-free).
Tafluprost is a PGA with pharmacological properties similar to those of latanoprost and it is characterized by the absence of preservatives (FOGAGNOLO et al., 2015; KWAK et al., 2017).
Of the four prostaglandin analogs, three have no human eye data, bimatoprost (Lumigan), tafluprost (Zioptan), and travoprost (Travatan Z).
The authors have previously reported that 60 minutes after administration of topical tafluprost, LSFG measurements of OBF increased significantly in the eyes of normal subjects and patients with normal tension glaucoma (NTG) (100% to 104.3 [+ or -] 6.6%, P < 0.01) [16].
The new treatment, tafluprost, contains none of the detergents that give rise to adverse reactions and is far more "patient friendly" than its predecessors.
Tafluprost, sold as Saflutan, contains none of the detergents that give rise to adverse reactions .
The tafluprost glaucoma drops are the first of their kind that avoid unpleasant side effects which can put patients off, including burning, itching, tears, or a "dry eye" sensation.
Tokyo, Japan, Feb 15, 2006 - (JCN) - Santen Pharmaceutical announced on February 14 the preliminary results of overseas clinical trials of DE-092 (olmesartan) and DE-085 (tafluprost), two drug candidates for the treatment of glaucoma.